The BRAF(T1799A) mutation confers sensitivity of thyroid cancer cells to the BRAF(V600E) inhibitor PLX4032 (RG7204)

Aberrant signaling of the Ras-Raf-MEK-ERK (MAP kinase) pathway driven by the mutant kinase BRAF(V600E), as a result of the BRAF(T1799A) mutation, plays a fundamental role in thyroid tumorigenesis. This study investigated the therapeutic potential of a BRAF(V600E)-selective inhibitor, PLX4032 (RG7204...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Biochem Biophys Res Commun
Asıl Yazarlar: Xing, Joanna, Liu, Ruixin, Xing, Mingzhao, Trink, Barry
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2010
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4596240/
https://ncbi.nlm.nih.gov/pubmed/21185263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbrc.2010.12.088
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller